Dr. Raj Live - Stem Cell Therapy
Dr. Raj discusses benefits of stem cell therapy.

By: SPORTSDOC RAJ

See the original post here:
Dr. Raj Live - Stem Cell Therapy - Video

Category: Science & Technology Posted: October 3, 2014 01:55PM Author: Guest_Jim_*

Heart attacks are pretty serious and something very hard to recover from, in part because heart cells do not multiply and there are few cardiac muscle stem cells to repair the damage. Cardiac patches have been created to replace damaged cells, but because of how they are made, these patches can cause their own health problems. Researchers at Tel Aviv University have recently developed a new hybrid patch that could address those problems.

Traditionally the patches are made by growing cardiac tissue on a collagen scaffold from pig hearts. One of the problems with this approach is the potential for antigens that will trigger an immune response, causing the patient's body to attack the patch. To get around this the researchers instead harvest fatty tissue from the patient's stomach, as the body will not attack its own cells. This left an issue with connectivity, as the cells in the patch must respond to the electrical signals of the heart, and engineered patches do not immediately form the necessary connections. The solution the researchers tried was to deposit gold nanoparticles onto the cardiac tissue, providing the needed conductivity.

So far the nonimmunogenic hybrid patch has shown itself to transfer electrical signals faster and more efficiently than scaffolds without the gold nanoparticles, when tested in animals. The next step for the technology is to test it in larger animals, and eventually perform clinical trials.

Source: American Friends of Tel Aviv University

Link:
Gold Nanoparticles Used to Improve Cardiac Patches

Stem Cell Therapy for Hair Growth
Award winning dr devesh clinic is pioneer in stem cell hair restoration in india. visit @ http://www.drdevesh.in http://www.hairtransplantsdelhi.in facebook page- prp hair india http://www.fb.com/biofuehairtransplant.

By: dr.devesh aggarwal

Excerpt from:
Stem Cell Therapy for Hair Growth - Video

The Goal of Cardiac Stem Cell Therapy at Okyanos
Leslie Miller, M.D., F.A.C.C. and Okyanos Chief Science Officer, describes the goal of treating congestive heart failure and coronary artery disease patients with their own fat-derived stem...

By: Okyanos Heart Institute

Here is the original post:
The Goal of Cardiac Stem Cell Therapy at Okyanos - Video

Because heart cells cannot multiply and cardiac muscles contain few stem cells, heart tissue is unable to repair itself after a heart attack. Now Tel Aviv University researchers are literally setting a new gold standard in cardiac tissue engineering.

Dr. Tal Dvir and his graduate student Michal Shevach of TAU's Department of Biotechnology, Department of Materials Science and Engineering, and Center for Nanoscience and Nanotechnology, have been developing sophisticated micro- and nanotechnological tools -- ranging in size from one millionth to one billionth of a meter -- to develop functional substitutes for damaged heart tissues. Searching for innovative methods to restore heart function, especially cardiac "patches" that could be transplanted into the body to replace damaged heart tissue, Dr. Dvir literally struck gold. He and his team discovered that gold particles are able to increase the conductivity of biomaterials.

In a study published by Nano Letters, Dr. Dvir's team presented their model for a superior hybrid cardiac patch, which incorporates biomaterial harvested from patients and gold nanoparticles. "Our goal was twofold," said Dr. Dvir. "To engineer tissue that would not trigger an immune response in the patient, and to fabricate a functional patch not beset by signalling or conductivity problems."

A scaffold for heart cells

Cardiac tissue is engineered by allowing cells, taken from the patient or other sources, to grow on a three-dimensional scaffold, similar to the collagen grid that naturally supports the cells in the heart. Over time, the cells come together to form a tissue that generates its own electrical impulses and expands and contracts spontaneously. The tissue can then be surgically implanted as a patch to replace damaged tissue and improve heart function in patients.

According to Dr. Dvir, recent efforts in the scientific world focus on the use of scaffolds from pig hearts to supply the collagen grid, called the extracellular matrix, with the goal of implanting them in human patients. However, due to residual remnants of antigens such as sugar or other molecules, the human patients' immune cells are likely to attack the animal matrix.

In order to address this immunogenic response, Dr. Dvir's group suggested a new approach. Fatty tissue from a patient's own stomach could be easily and quickly harvested, its cells efficiently removed, and the remaining matrix preserved. This scaffold does not provoke an immune response.

Using gold to create a cardiac network

The second dilemma, to establish functional network signals, was complicated by the use of the human extracellular matrix. "Engineered patches do not establish connections immediately," said Dr. Dvir. "Biomaterial harvested for a matrix tends to be insulating and thus disruptive to network signals."

At his Laboratory for Tissue Engineering and Regenerative Medicine, Dr. Dvir explored the integration of gold nanoparticles into cardiac tissue to optimize electrical signaling between cells. "To address our electrical signalling problem, we deposited gold nanoparticles on the surface of our patient-harvested matrix, 'decorating' the biomaterial with conductors," said Dr. Dvir. "The result was that the nonimmunogenic hybrid patch contracted nicely due to the nanoparticles, transferring electrical signals much faster and more efficiently than non-modified scaffolds."

Excerpt from:
A heartbeat away? Hybrid 'patch' could replace transplants

Stem Cell Therapy The Aspen Institute for Anti Aging Regenerative Medicine

By: Cupio Media

Read the original here:
Stem Cell Therapy The Aspen Institute for Anti Aging & Regenerative Medicine - Video

Stem Cell Therapy in Muscular Dystrophy - Woman
stem cell india, stem cell therapy india, stem cell in india, stem cell therapy in india, india stem cell, india stem cell therapy.

By: Stem Cell India

See the original post here:
Stem Cell Therapy in Muscular Dystrophy - Woman - Video

Basic Evaluation Before PRP and Stem Cell Therapy in Osteoarthritis Knee
stem cell india, stem cell therapy india, stem cell in india, stem cell therapy in india, india stem cell, india stem cell therapy.

By: Stem Cell India

See the rest here:
Basic Evaluation Before PRP and Stem Cell Therapy in Osteoarthritis Knee - Video

A teenager who gave stem cells to save the life of a stranger is backing a national campaign to find more donors.

In June, Celyn Evans, 17, became one of the youngest people in the UK to donate stem cells.

The Colchester Royal Grammar School sixth-form student is supporting Anthony Nolans Save a Life at 16 campaign.

The charity wants HMRC to include details about stem cell donation when it writes to teens with their National Insurance numbers ahead of their 16th birthday.

Celyn, of West Mersea, said: You often hear that young people are self absorbed and not interested in helping others, but I think thats wrong.

People just need to be made aware of how they can help. That is why I am supporting this campaign.

Celyn joined the bone marrow donor register last September when his brothers friend developed leukaemia.

He was not able to help the family friend, but in February, Anthony Nolan contacted him to say he was a possible match for another patient in need of a potentially life-saving transplant.

Celyn agreed to donate and, after a series of check-ups, made the donation in London in June.

Like 90 per cent of donors, he gave his stem cells through a simple, outpatient process similar to giving blood.

Read the original:
Colchester teen becomes one of the UK's youngest stem cell donors

When a child became ill, Jim Pattison was one of many who stepped up as a potential bone marrow donor.

Herald photo by Jodi Schellenberg

Jim Pattison was given two paperweights for his stem cell donation. He decided to become a donor in 1996, but was not a match until after 2010.

In 1996, Pattison was one of many who went on the bone marrow transplant list to help a one and a half year old child who was diagnosed with acute myeloid leukemia. The organizers of the donor drive expected maybe 50 people to show up and were shocked by the close to 400 who attended.

Sadly, the family didnt find a match and the girl died, but Pattison decided to stay on the registry.

They asked if I wanted to stay on and my answer was that if I would do it for Abigail I would do it for anybody, he said.

Throughout the years, Pattison was asked to test for more markers to see if he would be a match for someone else. He did his last test in 2010 and heard back a short time later with the news he was a match.

Pattison was chosen for a peripheral stem cell donation, which is different from a bone marrow transplant because it is less invasive.

I first went to where the stem cells are collected and had a physical, he explained. They sent me back with some drugs that I had to have injected here, that stimulate the stem cells to grow. I had four injections before I went.

They were looking to make sure I had a high enough level of stem cells to make the donation, he added.

More:
Local man shares his story of stem cell donation

Company plans for the future of stem cell use

by Samantha Schmieder

Staff Writer

Next Healthcare Inc. of Germantown recently launched a partnership with Arizona Cardinals wide reciever Larry Fitzgerald to promote its newest venture, CelBank Pro to other professional athletes.

Next Healthcares CelBank is the collection of cell samples and storage of their blood, skin or stem cells to be used in the future. Stem cells are unspecialized cells that are able to renew themselves through cell division and can be scientifically manipulated to become another type of cell with a more specialized function. They offer hope to provide new ways to fight disease or injuries, according to the National Institutes of Health.

Essentially we are in the business of banking cells for people, Vin Singh, the founder and CEO of Next Healthcare, said.

While CelBank is geared toward anyone interested in using their own cells later in their life, CelBank Pro is geared toward sports players who are very likely to get injured or just worn down during their career.

Skin cells and stem cells are stored at a healthy time at someones life for later use in regenerative medicine, Singh said.

In 2006 and 2007, Singh, who lives in Boyds, heard about a method in Japan that was able to turn adult skin cells into stem cells. Singh decided to build Next Healthcare around these induced pluripotent stem cells, or iPS cells.

For me that was the real spark. I heard about that and thought, Wow, this is an amazing, revolutionary breakthrough, Singh said. Thats where the idea came from, what can we do with that technology. There has to be something that I can do for consumers to give them an advantage.

See the rest here:
Germantown's Next Healthcare pairs with NFL player

Cellular therapeutics -- using intact cells to treat and cure disease -- is a hugely promising new approach in medicine but it is hindered by the inability of doctors and scientists to effectively track the movements, destination and persistence of these cells in patients without resorting to invasive procedures, like tissue sampling.

In a paper published September 17 in the online journal Magnetic Resonance in Medicine, researchers at the University of California, San Diego School of Medicine, University of Pittsburgh and elsewhere describe the first human tests of using a perfluorocarbon (PFC) tracer in combination with non-invasive magnetic resonance imaging (MRI) to track therapeutic immune cells injected into patients with colorectal cancer.

"Initially, we see this technique used for clinical trials that involve tests of new cell therapies," said first author Eric T. Ahrens, PhD, professor in the Department of Radiology at UC San Diego. "Clinical development of cell therapies can be accelerated by providing feedback regarding cell motility, optimal delivery routes, individual therapeutic doses and engraftment success."

Currently, there is no accepted way to image cells in the human body that covers a broad range of cell types and diseases. Earlier techniques have used metal ion-based vascular MRI contrast agents and radioisotopes. The former have proven difficult to differentiate in vivo; the latter raise concerns about radiation toxicity and do not provide the anatomical detail available with MRIs.

"This is the first human PFC cell tracking agent, which is a new way to do MRI cell tracking," said Ahrens. "It's the first example of a clinical MRI agent designed specifically for cell tracking."

Researchers used a PFC tracer agent and an MRI technique that directly detects fluorine atoms in labeled cells. Fluorine atoms naturally occur in extremely low concentrations in the body, making it easier to observe cells labeled with fluorine using MRI. In this case, the modified and labeled dendritic cells -- potent stimulators of the immune system -- were first prepared from white blood cells extracted from the patient. The cells were then injected into patients with stage 4 metastatic colorectal cancer to stimulate an anti-cancer T-cell immune response.

The published study did not assess the efficacy of the cell therapy, but rather the ability of researchers to detect the labeled cells and monitor what happened to them. Ahrens said the technique worked as expected, with the surprising finding that only half of the delivered cell vaccine remained at the inoculation site after 24 hours.

"The imaging agent technology has been to shown to be able to tag any cell type that is of interest," Ahrens said. "It is a platform imaging technology for a wide range of diseases and applications," which might also speed development of relevant therapies.

"Non-invasive cell tracking may help lower regulatory barriers," Ahrens explained. "For example, new stem cell therapies can be slow to obtain regulatory approvals in part because it is difficult, if not impossible, with current approaches to verify survival and location of transplanted cells. And cell therapy trials generally have a high cost per patient. Tools that allow the investigator to gain a 'richer' data set from individual patients mean it may be possible to reduce patient numbers enrolled in a trial, thus reducing total trial cost."

Story Source:

See original here:
Better way to track emerging cell therapies using MRIs

11 hours ago A new method resulted in a colony of stem cells, glowing green, derived from one adult immune cell. Credit: Laboratory of Matthias Stadtfeld at NYU Langone Medical center

Scientists at NYU Langone Medical Center have found a way to boost dramatically the efficiency of the process for turning adult cells into so-called pluripotent stem cells by combining three well-known compounds, including vitamin C. Using the new technique in mice, the researchers increased the number of stem cells obtained from adult skin cells by more than 20-fold compared with the standard method. They say their technique is efficient and reliable, and thus should generally accelerate research aimed at using stem cells to generate virtually any tissue. Stem cells are immature or uncommitted cells that are theoretically capable of becoming any cell type.

"This big boost in efficiency gives us an opportunity now to study stem cell programming mechanisms at high resolution," says Matthias Stadtfeld, PhD, assistant professor of cell biology and a member of the Skirball Institute of Biomolecular Medicine and the Helen L. and Martin S. Kimmel Center for Stem Cell Biology at NYU Langone Medical Center, who led the research.

"This is a very exciting advance," says Ruth Lehmann, PhD, director of the Kimmel Center for Stem Cell Biology and the Skirball Institute at NYU Langone and chair of the Department of Cell Biology. "The new technology developed by the Stadtfeld lab to reprogram differentiated cells efficiently and effectively brings the prospect of stem cell technology for safe use in regenerative medicine ever so much closer."

The standard method for reprogramming skin, blood, or other tissue-specific cell types into "induced pluripotent stem cells" (iPSCs) was reported in 2006 by the laboratory of Kyoto University's Shinya Yamanaka, who later won a Nobel Prize for the achievement. The method involves the artificial expression of four key genes dubbed OKSM (for Oct4, Klf4, Sox2 and myc) whose collective activity slowly prods cells into an immature state much like that of an early embryonic cell.

In principle, one could take a sample of cells from a person, induce the cells to become iPSCs, then multiply the iPSCs in a lab dish and stimulate them to mature towards desired adult cell types such as blood, brain or heartwhich then could be used to replace injured or diseased tissue in that same individual.

But there are many formidable technical obstacles, among which is the low efficiency of currently used protocols. Converting most cell types into stable iPSCs occurs at rates of 1 percent or less, and the process can take weeks.

Researchers throughout the world have been searching for ways to boost this efficiency, and in some cases have reported significant gains. These procedures, however, often alter vital cellular genes, which may cause problems for potential therapies. For the new study, reported online today in Stem Cell Reports, Dr. Stadtfeld and his laboratory team decided to take a less invasive approach and investigate chemical compounds that transiently modulate enzymes that are present in most cells. "We especially wanted to know if these compounds could be combined to obtain stem cells at high efficiency," Dr. Stadtfeld says.

Two of these compounds influence well known signaling pathways, called Wnt and TGF-, which regulate multiple growth-related processes in cells. The third is vitamin C (also known as ascorbic acid). Best known as a powerful antioxidant, the vitamin was recently discovered to assist in iPSC induction by activating enzymes that remodel chromatinthe spiral scaffold for DNAto regulate gene expression.

Simon Vidal, a graduate student in the Stadtfeld lab, and Bhishma Amlani, a postdoctoral researcher, looked first at mouse skin fibroblasts, the most common cell type used for iPSC research. Adding to fibroblasts engineered to express OKSM either vitamin C, a compound to activate Wnt signaling, or a compound to inhibit TGF- signaling increased iPSC-induction efficiency weakly to about 1% after a week of cell culture. Combining any two worked a bit better. But combining all three brought the efficiency to about 80 percent in the same period of time.

More here:
Team reports reliable, highly efficient method for making stem cells

Kickstarter Promo Update Sept 15 2014 - Stem Cell Treatment for Hope, Love and Freedom
Hello my name is Sonny, I was born with a nerve disease, a genetic mutation that causes the muscles in my arms, hands, legs and feet to atrophy and to become weak. I now have perfect legs....for...

By: Sonny Davis

Original post:
Kickstarter Promo Update Sept 15 2014 - Stem Cell Treatment for Hope, Love and Freedom - Video

Laminine Testimonials stroke
Laminine is availabe in the Philippines!!! "The Closest Alternative To Stem Cell Therapy..." "The miracle formula from a 9-day-old fertilized hen eggs" For More Info About Laminine, How a...

By: Karl Angelo Alipin

Visit link:
Laminine Testimonials stroke - Video

TOKYO: Japanese researchers on Friday (Sep 12) conducted the world's first surgery to implant "iPS" stem cells in a human body in a major boost to regenerative medicine, two institutions involved said.

A female patient in her 70s with age-related macular degeneration (AMD), a common medical condition that can lead to blindness in older people, had a sheet of retina cells that had been created from iPS cells implanted. "It is the first time in the world that iPS cells have been transplanted into a human body," a spokeswoman for Riken, one of the research institutions, told AFP.

The research team used induced Pluripotent Stem (iPS) cells - which have the potential to develop into any cell in the body - that had originally come from the skin of the patient. Until the discovery of iPS several years ago, the only way to obtain stem cells was to harvest them from human embryos.

"We feel very much relieved," ophthalmologist Masayo Takahashi, the leader of the project at Riken, told a news conference after the surgery in Kobe. "We want to take it as a big step forward. But we must go on and on from here."

In a statement, the institution said that "no serious adverse phenomena such as excessive bleeding occurred" during the two-hour procedure. The surgery is still at an experimental stage, but if it is successful, doctors hope it will stop the deterioration in vision that comes with AMD.

The patient - one of six expected to take part in the trial - will be monitored over the next four years to determine how well the implants have performed, whether the body has accepted them and if they have become cancerous.

AMD, a condition that is incurable at present, affects mostly middle-aged and older people and can lead to blindness. It afflicts around 700,000 people in Japan alone.

The study was being carried out by researchers from government-backed research institution Riken and the Institute of Biomedical Research and Innovation Hospital.

Stem cell research is a pioneering field that has excited many in the scientific community with the potential they believe it offers. Stem cells are infant cells that can develop into any part of the body. Harvesting from human embryos is controversial because it requires the destruction of the embryo, a process to which religious conservatives, among others, object.

Groundbreaking work done in 2006 by Shinya Yamanaka at Kyoto University, a Nobel Laureate in medicine last year, succeeded in generating stem cells from adult skin tissue.

See the original post here:
Japan carries out first iPS stem cell retina surgery

Wichita, KS (PRWEB) September 10, 2014

Ryan Benton, a 28 year-old Duchennes muscular dystrophy patient from Wichita, Kansas, received his first umbilical cord tissue-derived mesenchymal stem cell treatment yesterday following US FDA approval of his doctors application for a single patient, investigational new drug (IND) for compassionate use.

Duchenne muscular dystrophy (DMD) is a rapidly progressive form of muscular dystrophy that occurs primarily in boys. It is caused by an alteration (mutation) in a gene, called the DMD gene, which causes the muscles to stop producing the protein dystrophin. Individuals who have DMD experience progressive loss of muscle function and weakness, which begins in the lower limbs and leads to progressively worsening disability. Death usually occurs by age 25, typically from lung disorders. There is no known cure for DMD.

This trial, officially entitled Allogeneic transplantation of human umbilical cord mesenchymal stem cells (UC-MSC) for a single male patient with Duchenne Muscular Dystrophy (DMD) marks the first time the FDA has approved an investigational allogeneic stem cell treatment for Duchennes in the United States.

Ryan received his first intramuscular stem cell injections from allergy and immunology specialist, Van Strickland, M.D at Asthma and Allergy Specialists in Wichita, Kansas. He will receive 3 more treatments this week on consecutive days. Dr. Strickland will administer similar courses to Ryan every 6 months for a total of 3 years.

This is not the first time Ryan has undergone umbilical cord mesenchymal stem cell therapy. Since 2009, Ryan has been traveling to the Stem Cell Institute in Panama for similar treatments. Encouraging results from these treatments prompted Dr. Strickland to seek out a way to treat Ryan in the United States.

The stem cell technology being utilized in this trial was developed by renowned stem cell scientist Neil H. Riordan, PhD. Dr. Riordan is the founder and president of the Stem Cell Institute in Panama City, Panama and Medistem Panama. Medistem Panama is providing cell harvesting and banking services for their US-based cGMP laboratory partner.

Funding for this trial is being provided by the Aidan Foundation, a non-profit organization founded by Dr. Riordan in 2004 to provide financial assistance for alternative therapies to people like Ryan.

About Van Strickland, MD

Dr. Strickland came to Wichita in 1979 from his fellowship at the National Jewish Hospital in Denver. Since then he has spent one year in Wyoming, one year in Dallas, Texas and one year in Lees Summit Missouri before returning to full-time practice in Wichita, Kansas.

Read more from the original source:
After FDA Approval, Duchennes Muscular Dystrophy Patient Receives First Umbilical Cord Stem Cell Treatment in the ...

Father-of-two James Cross, 55, suffered a heart attack in February Surgeons at the London Chest Hospital offered him a unique chance Experimental therapy involved injecting stem cells from Mr Cross's hip into his heart in the hope they would encourage the organ to repair itself It appears to have worked as Mr Cross's heart muscle function has increased from 21% after the attack to 37% and it is still improving Experts hope the new technique will increase survival rates by a quarter

By John Naish

Published: 20:38 EST, 8 September 2014 | Updated: 07:12 EST, 9 September 2014

James Cross, 55,was offered experimental treatment after suffering a heart attack in February

After James Cross had a heart attack in February, he was given a unique chance for a new life.

Surgeons at the London Chest Hospital offered the 55-year-old experimental therapy that involved injecting his own stem cells into the damaged organ.

This was done in the hope that it would encourage his heart to repair itself.

The injected stem cells should prevent the hearts muscle tissue from becoming increasingly damaged after suffering a lack of oxygen during the heart attack.

And it seems to have worked.

After the heart attack, I had 21 per cent of my heart muscle functioning, as opposed to the normal 61 per cent, says James.

See the original post here:
Could stem cells from your hip repair your heart after an attack?

Researchers at Sanford-Burnham Medical Research Institute (Sanford-Burnham) have developed a novel technique to promote tissue repair in damaged muscles. The technique also creates a sustainable pool of muscle stem cells needed to support multiple rounds of muscle repair. The study, published September 7 in Nature Medicine, provides promise for a new therapeutic approach to treating the millions of people suffering from muscle diseases, including those with muscular dystrophies and muscle wasting associated with cancer and aging.

There are two important processes that need to happen to maintain skeletal-muscle health. First, when muscle is damaged by injury or degenerative disease such as muscular dystrophy, muscle stem cells -- or satellite cells -- need to differentiate into mature muscle cells to repair injured muscles. Second, the pool of satellite cells needs to be replenished so there is a supply to repair muscle in case of future injuries. In the case of muscular dystrophy, the chronic cycles of muscle regeneration and degeneration that involve satellite-cell activation exhaust the muscle stem-cell pool to the point of no return.

"Our study found that by introducing an inhibitor of the STAT3 protein in repeated cycles, we could alternately replenish the pool of satellite cells and promote their differentiation into muscle fibers," said Alessandra Sacco, Ph.D., assistant professor in the Development, Aging, and Regeneration Program at Sanford-Burnham. "Our results are important because the process works in mice and in human muscle cells."

"Our next step is to see how long we can extend the cycling pattern, and test some of the STAT3 inhibitors currently in clinical trials for other indications such as cancer, as this could accelerate testing in humans," added Sacco.

"These findings are very encouraging. Currently, there is no cure to stop or reverse any form of muscle-wasting disorders -- only medication and therapy that can slow the process," said Vittorio Sartorelli, M.D., chief of the Laboratory of Muscle Stem Cells and Gene Regulation and deputy scientific director at the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS). "A treatment approach consisting of cyclic bursts of STAT3 inhibitors could potentially restore muscle mass and function in patients, and this would be a very significant breakthrough."

Revealing the mechanism of STAT3

STAT3 (signal transducer and activator of transcription 3) is a protein that activates the transcription of genes in response to IL-6, a signaling protein released by cells in response to injury and inflammation. Prior to the study, scientists knew that STAT3 played a complex role in skeletal muscle, promoting tissue repair in some instances and hindering it in others. But the precise mechanism of how STAT3 worked was a mystery.

The research team first used normally aged mice and mice models of a form of muscular dystrophy that resembles the human disease to see what would happen if they were given a drug to inhibit STAT3. They found that the inhibitor initially promoted satellite-cell replication, followed by differentiation of the satellite cells into muscle fibers. When they injected the STAT3 inhibitor every seven days for 28 days, they found an overall improvement in skeletal-muscle repair, and an increase in the size of muscle fibers.

"We were pleased to find that we achieved similar results when we performed the experiments in human muscle cells," said Sacco. "We have discovered that by timing the inhibition of STAT3 -- like an "on/off" light switch -- we can transiently expand the satellite-cell population followed by their differentiation into mature muscle cells."

Story Source:

See the rest here:
Researchers discover key to making new muscles

Beverly Hills, California (PRWEB) September 08, 2014

Beverly Hills Orthopedic Institute has become an R3 Stem Cell Center of Excellence. Patients are immediately able to benefit from the regenerative medicine procedures at the Center, including bone marrow or amniotic derived stem cells for arthritis, sports injuries, and all types of chronic pain issues. Call R3 Stem Cell for scheduling at (844) GET-STEM.

R3 Stem Cell works with the best Board Certified providers nationwide, bringing the latest cutting edge regenerative medicine procedures to those in need. The top Beverly Hills orthopedic surgeon, Dr. Raj, is the medical director of Beverly Hills Orthopedic Institute and has performed over 50 stem cell procedures to date. Patients have include elite athletes, celebrities, executives, students, manual laborers and senior citizens. In other words, every walk of life can benefit.

The procedures offered include stem cell therapy for arthritis, back pain, cartilage defects, tendonitis, migraines, fracture healing and ligament injuries. The procedures are often able to help patients avoid the need for surgery and provide excellent pain relief with increased function.

Said R3 CEO Bob Maguire, MBA, Dr. Raj is a highly respected, skilled and compassionate provider who is committed to providing cutting edge options to his patients. It can help them heal faster while achieving pain relief. Thats what R3 Centers of Excellence strive for and have been very successful with to date.

Several different types of regenerative medicine procedures are offered at the R3 Center of Excellence. Amniotic stem cell procedures have shown amazing benefits in small studies to date. The fluid is obtained from consenting donors after a scheduled c-section, with the material being processed at an FDA regulated lab. No fetal tissue is involved or embryonic stem cells.

Bone marrow aspirate stem cell therapy is also offered, with the same day procedure injecting the processed bone marrow into the problem area. A high concentration of stem cells and growth factors sparks an impressive healing process, which can often regenerate damaged tissue.

Platelet rich plasma therapy is also offered, which involves a simple blood draw from patients. Studies are beginning to show that the regenerative medicine procedures work well for helping patients avoid the need for joint replacement surgery and also assisting athletes to get back on the field faster than otherwise.

Financing is available for the procedures at all R3 Stem Cell Centers of Excellence. Call (844) GET-STEM for more information and scheduling with stem cell treatment Los Angeles trusts.

Read more from the original source:
Beverly Hills Orthopedic Institute Becomes R3 Stem Cell Center of Excellence